IBEC and Vitala, a spin-off founded by IBEC researchers, are set to participate in three public-private partnership projects, with a combined investment nearing €4 million. These initiatives, backed by the Spanish Ministry of Science and Innovation and the State Research Agency, aim to advance remote health monitoring, create an oral drug for Inflammatory Bowel Disease, and enhance 13C magnetic resonance imaging for therapeutic research. Leveraging cutting-edge technological approaches, these endeavors aspire to make a positive impact on the fields of medicine and biomedical research.
For the sixth consecutive year, IBEC has successfully hosted its ‘Mad for Bioengineering’ course with the support of the Catalunya La Pedrera Foundation. Geared towards 1st-year high school students interested in STEM careers, the program provides a unique immersion in the field of bioengineering, addressing health issues from a multidisciplinary perspective. The closing ceremony, attended by students and their families, featured presentations of final projects and the awarding of diplomas.
The researcher at the Institute for Bioengineering of Catalonia has been awarded an ERC Consolidator Grant. This prestigious European funding supports excellent scientists and scholars who are consolidating their independent research teams to pursue their most promising scientific ideas. The €2 million grant over 5 years will allow Bolognesi and her team to develop a new method for identifying mutations that lead to the formation of amyloids—aggregates of proteins that contribute to a variety of diseases, including Alzheimer’s and Parkinson’s.
The IBEC is set to lead the coordination of the PHOTOTHERAPORT project, which will be developed with funding from the European Innovation Council’s Pathfinder Open programme. The project focuses on the development of luminescent implants and light-activated drugs for innovative neuromodulation therapies. PHOTOTHERAPORT will comprise an international consortium of 8 institutions and will receive €3 million over 3 years for the preclinical study of these implants.
IBEC researcher Samuel Sánchez has been honored with the 2023 Constantes y Vitales Award in the “Young Talent in Biomedical Research” category for his work on designing self-propelled nanorobots capable of delivering drugs within the human body. This initiative, presented by LaSexta and AXA Foundation, aims to foster biomedical research in Spain and spotlight the contributions of its scientists.
A pioneering study led by IBEC in collaboration with ICFO has unveiled a method to control brain activity in living organisms using drugs activated by infrared light. This cutting-edge technique activates a specific neurotransmitter receptor using light that can penetrate deep into tissue and offers unparalleled pharmacological and spatiotemporal precision in three dimensions. The findings open new frontiers for neurobiology research and the development of light-based noninvasive neuromodulation therapies.
IBEC’s 16th annual Symposium focused on ‘Bioengineering for Future and Precision Medicine,’ one of IBEC’s three key application areas. Approximately 300 people attended the event, including local and international researchers. It provided a multidisciplinary environment where experts from other institutions and the IBEC community had the opportunity to present their projects and exchange knowledge.
IBEC showcases its technological capabilities to foster new partnerships at BIOSPAIN. IBEC representatives actively participated in the BIOSPAIN conference, seizing the opportunity to highlight the institute’s advancements in science and technology. Over the three days of the event, they presented various aspects, ranging from basic research to the coordination of state plans and technology transfer conducted at IBEC. BIOSPAIN, a premier congress in Europe, brings together more than 850 innovative entities specializing in health, sustainable agri-food practices, and solutions against climate change.